Linked Life Data

19385967

Source:http://linkedlifedata.com/resource/pubmed/id/19385967

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19385967rdf:typepubmed:Citationlld:pubmed
pubmed-article:19385967lifeskim:mentionsumls-concept:C0006142lld:lifeskim
pubmed-article:19385967lifeskim:mentionsumls-concept:C1516213lld:lifeskim
pubmed-article:19385967lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:19385967lifeskim:mentionsumls-concept:C0111429lld:lifeskim
pubmed-article:19385967lifeskim:mentionsumls-concept:C0038952lld:lifeskim
pubmed-article:19385967lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:19385967lifeskim:mentionsumls-concept:C0024708lld:lifeskim
pubmed-article:19385967lifeskim:mentionsumls-concept:C0681842lld:lifeskim
pubmed-article:19385967lifeskim:mentionsumls-concept:C1522673lld:lifeskim
pubmed-article:19385967lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:19385967lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:19385967pubmed:issue6lld:pubmed
pubmed-article:19385967pubmed:dateCreated2009-6-8lld:pubmed
pubmed-article:19385967pubmed:abstractTextAnthracycline-based chemotherapy represents a milestone in the treatment of breast cancer. We previously demonstrated in an in vitro model that cyclin E overexpression is associated with increased expression of manganese superoxide dismutase (MnSOD) and resistance to doxorubicin. In the present study, immunohistochemical expression of cyclin E and MnSOD was evaluated in 134 early breast cancer patients receiving adjuvant epirubicin-based chemotherapy regimens containing epirubicin. Both parameters were correlated with the available clinicopathological parameters and with the outcome of patients. Overexpression of cyclin E and MnSOD was detected in 46 (34.3%) and 56 (41.8%) patients, respectively, and expression levels of the two proteins were related. Disease-free and alive patients displayed a lower mean percentage of cyclin E-expressing cells than relapsed and dead patients, respectively. Kaplan-Meier survival analysis demonstrated a significant separation between high versus low cyclin E-expressing tumors in terms of overall survival (P = 0.038 by log-rank). Similar results were obtained considering the subset of node-negative patients separately. No significant relationship with patient outcome was observed for MnSOD expression levels. At multivariate analysis cyclin E failed to demonstrate an independent prognostic value. In conclusion, the results of the present study support previous evidence that increased cyclin E expression is associated with higher MnSOD expression levels and poorer outcome, at least as evaluated in terms of overall survival. Further studies are warranted to evaluate the usefulness of cyclin E as a prognostic marker to identify breast cancer patients at higher risk of death from the disease when treated with adjuvant anthracycline-based therapy.lld:pubmed
pubmed-article:19385967pubmed:languageenglld:pubmed
pubmed-article:19385967pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19385967pubmed:citationSubsetIMlld:pubmed
pubmed-article:19385967pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19385967pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19385967pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19385967pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19385967pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19385967pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19385967pubmed:statusMEDLINElld:pubmed
pubmed-article:19385967pubmed:monthJunlld:pubmed
pubmed-article:19385967pubmed:issn1349-7006lld:pubmed
pubmed-article:19385967pubmed:authorpubmed-author:SgambatoAless...lld:pubmed
pubmed-article:19385967pubmed:authorpubmed-author:MigaldiMarioMlld:pubmed
pubmed-article:19385967pubmed:authorpubmed-author:CittadiniAchi...lld:pubmed
pubmed-article:19385967pubmed:authorpubmed-author:BevilacquaGen...lld:pubmed
pubmed-article:19385967pubmed:authorpubmed-author:ScambiaGiovan...lld:pubmed
pubmed-article:19385967pubmed:authorpubmed-author:RossiGiulioGlld:pubmed
pubmed-article:19385967pubmed:authorpubmed-author:CollecchiPaol...lld:pubmed
pubmed-article:19385967pubmed:authorpubmed-author:MasciulloVale...lld:pubmed
pubmed-article:19385967pubmed:authorpubmed-author:CameriniAndre...lld:pubmed
pubmed-article:19385967pubmed:authorpubmed-author:CapodannoAles...lld:pubmed
pubmed-article:19385967pubmed:authorpubmed-author:AmorosoDomeni...lld:pubmed
pubmed-article:19385967pubmed:authorpubmed-author:GrazianiCrist...lld:pubmed
pubmed-article:19385967pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19385967pubmed:volume100lld:pubmed
pubmed-article:19385967pubmed:ownerNLMlld:pubmed
pubmed-article:19385967pubmed:authorsCompleteYlld:pubmed
pubmed-article:19385967pubmed:pagination1026-33lld:pubmed
pubmed-article:19385967pubmed:meshHeadingpubmed-meshheading:19385967...lld:pubmed
pubmed-article:19385967pubmed:meshHeadingpubmed-meshheading:19385967...lld:pubmed
pubmed-article:19385967pubmed:meshHeadingpubmed-meshheading:19385967...lld:pubmed
pubmed-article:19385967pubmed:meshHeadingpubmed-meshheading:19385967...lld:pubmed
pubmed-article:19385967pubmed:meshHeadingpubmed-meshheading:19385967...lld:pubmed
pubmed-article:19385967pubmed:meshHeadingpubmed-meshheading:19385967...lld:pubmed
pubmed-article:19385967pubmed:meshHeadingpubmed-meshheading:19385967...lld:pubmed
pubmed-article:19385967pubmed:meshHeadingpubmed-meshheading:19385967...lld:pubmed
pubmed-article:19385967pubmed:meshHeadingpubmed-meshheading:19385967...lld:pubmed
pubmed-article:19385967pubmed:meshHeadingpubmed-meshheading:19385967...lld:pubmed
pubmed-article:19385967pubmed:meshHeadingpubmed-meshheading:19385967...lld:pubmed
pubmed-article:19385967pubmed:meshHeadingpubmed-meshheading:19385967...lld:pubmed
pubmed-article:19385967pubmed:meshHeadingpubmed-meshheading:19385967...lld:pubmed
pubmed-article:19385967pubmed:meshHeadingpubmed-meshheading:19385967...lld:pubmed
pubmed-article:19385967pubmed:meshHeadingpubmed-meshheading:19385967...lld:pubmed
pubmed-article:19385967pubmed:meshHeadingpubmed-meshheading:19385967...lld:pubmed
pubmed-article:19385967pubmed:meshHeadingpubmed-meshheading:19385967...lld:pubmed
pubmed-article:19385967pubmed:year2009lld:pubmed
pubmed-article:19385967pubmed:articleTitleCyclin E correlates with manganese superoxide dismutase expression and predicts survival in early breast cancer patients receiving adjuvant epirubicin-based chemotherapy.lld:pubmed
pubmed-article:19385967pubmed:affiliationGiovanni XXIII Cancer Research Center, Catholic University of Sacred Heart, Rome, Italy. asgambato@rm.unicatt.itlld:pubmed
pubmed-article:19385967pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19385967pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:6648entrezgene:pubmedpubmed-article:19385967lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19385967lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19385967lld:entrezgene